Literature DB >> 16292454

Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.

A K Gupta1, J R Schouten, L E Lynch.   

Abstract

Onychomycosis is prevalent in the Canadian population, and risk factors, such as old age and diabetes, are increasing. This condition has traditionally been treated using oral antifungal agents with varying degrees of success. Recently, ciclopirox nail lacquer 8% solution became the first topical agent approved in Canada for onychomycosis. Ciclopirox nail lacquer may be safe and effective for the treatment of onychomycosis, and certain candidates may benefit from therapy. Ciclopirox may be implicated for prophylactic use in order to prevent recurrent infection and may be used in combination with oral agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292454

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  2 in total

Review 1.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.

Authors:  Alessandro Subissi; Daniela Monti; Giuseppe Togni; Federico Mailland
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

2.  Treatment of onychomycosis: an update.

Authors:  A A Shirwaikar; T Thomas; A Shirwaikar; R Lobo; K S Prabhu
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.